Rare disease FDA re-rating
The agency accepted Agios’ mitapivat sickle-cell filing for priority review after a missed co-primary. The PDUFA date is November 1. “No advisory committee” is still a podcast prior, not company paper. Names the market had left for dead are repricing. Acceptance is not approval.
Through mid-2026, a post-DOGE Food and Drug Administration has been signalling openness to rare and orphan programs that would previously have been turned away. Agios took mitapivat back after the RISE UP trial missed its sickle-cell pain-crisis co-primary. The agency accepted the supplemental filing for priority review. The confirm is that acceptance, not an approval. Biotech investors read it as a regulatory right-shift — a lower efficacy bar that moves the probability-of-success distribution for a class of left-for-dead refiles.
The Agios signal
The July 7 Agios press release confirms the date: PDUFA November 1, 2026, priority review, accelerated pathway. File it as a mitapivat supplemental NDA, not a PYRUKYND-branded sickle-cell filing. The missed endpoint is in the November 19, 2025 RISE UP release — hemoglobin met, sickle-cell pain crises at p=0.1213 did not. Do not file “approved despite a missed VOC.” Approval has not happened. The confirmatory trial, REIGNITE, has dosed a first patient and is recruiting. Eric Schmidt, a biotech analyst, described the filing on the Biotech Hangout podcast: after talking to the FDA, Agios moved forward, and the filing was accepted for priority review. “If anyone needed any sign or signal that the FDA is open for business with regard to pretty much seems any orphan or rare disease opportunity, here it is yet again.” His “no ADCOM” line is not in the July 7 or July 30 company releases. Leave it unverified.
Paul Matteis put numbers on the re-rate. "If you used to assume that Replimune or Agios had a 10 or 20% probability of success, I don't know, I'd probably put that well above 50% for both of those two drugs right now." He immediately hedged: "Every situation is different. I don't think we should assume all of this is just unequivocally gonna go in favor of the sponsors."
The panel extended the right-shift to Dyne Therapeutics, whose DMD exon-skipper faces a late-January PDUFA. Brian Scorney argued that on "pretty much every metric it's better than a Teplerson" and predicted approval given the benchmark set by Sarepta years ago. Replimune’s Cellular, Tissue, and Gene Therapies Advisory Committee then voted 10 to 3 that IGNYTE efficacy results are “evaluable and clinically meaningful.” That is a panel vote, not an approval. Agios’s PDUFA is still November 1. “No ADCOM” on that file is still unverified. REIGNITE is still recruiting.
We're dealing with an FDA that's really been decimated and has lost a lot of seasoned people. And that makes it a lot harder to be, instead of lax or tough, just get it right.
Matt Herper, Biotech Hangout
The countervailing force is capacity, not hostility. DOGE cuts and senior departures — including Peter Marks and Marty Makary's predecessor Janet Woodcock's successor Verdun — mean the agency is less able to "just get it right." A decimated FDA may be erratic, not reliably lenient. The walk-back of complete-response-letter transparency — no CRLs released since April — removes the investor information edge on exactly these decisions.
The tradeable expression is a basket, not a single name: Agios, Replimune, with lateral optionality in uniQure, Sarepta, and Regenxbio. The forcing function is regulatory posture, which applies unevenly across programs.
The silencer consolidation
A separate read on rare-disease biotech runs through transthyretin amyloidosis, not through FDA posture. AstraZeneca and Ionis' eplontersen showed no benefit on top of background tafamidis in ATTR cardiomyopathy. The European Society of Cardiology meeting, August 28–30, published the overall miss: risk ratio 0.89, P=0.277. On tafamidis — all 819 patients who started on a stabilizer — the clinical result was still a null, risk ratio 1.14, P=0.39, and NT-proBNP P=0.08. Monotherapy was nominally positive. The July “global biomarker-null” line does not hold. Paul Matteis’s earlier read — "There's not even a biological effect" — now has to live next to that monotherapy slice. The dated ESC catalyst is closed. TRITON-CM is still recruiting, still adjunctive, still without outcomes, around 2030.
Alnylam's stock opened up about 17% on the readout, on the idea that it would now own the silencer market. Josh Schimmer saw a three-way battle remaining among BridgeBio, Alnylam, and Pfizer, with Bridge and Alnylam picking up the most share on differentiated product profiles.
The bull read carries a load-bearing risk. Alnylam's nucresiran is in a cardiovascular outcomes study where the vast majority of patients will be on tafamidis at baseline — essentially an adjunctive study. The eplontersen null is direct counter-evidence that silencers add benefit on modern tafamidis. Some on the panel think "we may never see another positive TTR cardiomyopathy readout again." An alternative explanation — ASO-specific cardiotoxicity or a stronger-than-modelled tafamidis effect — would confine the failure to eplontersen and not read across to Alnylam's siRNA silencer.
A high-profile refile rejection — or Agios or Replimune failing at PDUFA despite acceptance — would show the Agios acceptance was program-specific, not a posture. The capacity-depletion risk cuts directly against reliability even if leniency persists.